News
CCA ONTIER advised Lymphact - Lymphocyte Activation Technologies, S.A., a startup of Portugal Ventures and Busy Angels portfolio, on its sale to the British company Gamma Delta Therapeutics, specialized in T-cell delta technology.
The CCA ONTIER team involved in this operation was led by Domingos Cruz and constituted by Rita Trabulo, Associate Coordinator of the Corporate/M&A Department, and Rita Saias, Associate of the same department.
For Domingos Cruz 'this sale operation of Lymphact is notable to all titles. A company dedicated exclusively to R&D and that developed, thanks to the knowledge and genius of its founders, an innovative technology that promises to revolutionize the cure of cancer. It is not every day that M&A operations in Portugal are carried out with the sole aim of ensuring the transfer of technology. It is, therefore, one more evidence that the Portuguese startup's ecosystem is in good health and it is recommended'.
Lymphact is a biopharmaceutical startup focused on the development of personalized medical treatments, that created a technological platform that can generate autologous and heterologous cellular immune therapies for clinical applications - DOT-Cells®.